Showing 1 - 6 of 6
clinical trial design complexity. The results suggest that targeted regulatory innovation can shorten R&D periods without …
Persistent link: https://www.econbiz.de/10013477204
This paper introduces a newly digitized, open-access version of the Food and Drug Administration's "Orange Book"--a linkage between approved small-molecule drugs and the patents that protect them. The Orange Book also reports any applicable regulatory exclusivity that prevents competitive entry....
Persistent link: https://www.econbiz.de/10013462677
We investigate whether increased racial diversity of clinical trial principal investigators could increase the enrollment of Black patients, which currently lags population and disease-burden shares. We conducted a survey experiment in which respondents were shown a photo of a current NIH...
Persistent link: https://www.econbiz.de/10014372489
This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …
Persistent link: https://www.econbiz.de/10014447297
We investigate women's fertility, labor and marriage market responses to a health innovation that led to reductions in …
Persistent link: https://www.econbiz.de/10013361971
Operation Warp Speed (OWS) was a U.S. government-led program to accelerate the development, production, and administration of COVID-19 vaccines. The program cut the typical ten-year timeline needed to develop a new vaccine down to ten months and began vaccinating vulnerable populations within a...
Persistent link: https://www.econbiz.de/10015056157